Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) have received a consensus recommendation of "Buy" from the ten ratings firms that are covering the firm, MarketBeat reports. Seven equities research analysts have rated the stock with a buy recommendation and three have issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $17.56.

TRVI has been the subject of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Trevi Therapeutics in a research note on Tuesday, April 8th. D. Boral Capital reissued a "buy" rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Raymond James upgraded Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and increased their price target for the company from $9.00 to $29.00 in a report on Monday, March 10th. Oppenheimer upped their price objective on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and set a $12.50 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, CEO Jennifer L. Good sold 5,263 shares of the stock in a transaction dated Friday, March 21st. The shares were sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. This represents a 2.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Farrell Simon sold 81,313 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company's stock, valued at $519,075. The trade was a 51.39 % decrease in their position. The disclosure for this sale can be found here. Insiders own 24.37% of the company's stock.

Institutional Trading of Trevi Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TRVI. Summit Investment Advisors Inc. boosted its position in Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company's stock valued at $26,000 after buying an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Trevi Therapeutics by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company's stock valued at $40,000 after purchasing an additional 6,764 shares during the period. Raymond James Financial Inc. bought a new position in shares of Trevi Therapeutics in the 4th quarter valued at about $49,000. Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics during the 4th quarter worth approximately $58,000. Finally, Two Sigma Advisers LP acquired a new stake in Trevi Therapeutics during the 4th quarter worth $66,000. Institutional investors and hedge funds own 95.76% of the company's stock.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI traded down $0.09 during mid-day trading on Friday, reaching $6.01. The company had a trading volume of 140,402 shares, compared to its average volume of 1,900,868. The stock's 50 day moving average is $5.42 and its 200-day moving average is $4.12. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The stock has a market capitalization of $581.06 million, a PE ratio of -13.62 and a beta of 0.41.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.01. On average, sell-side analysts anticipate that Trevi Therapeutics will post -0.49 EPS for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.